Skip to main
VKTX
VKTX logo

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics Inc. is positioned favorably within the expanding obesity treatment market due to its advancements in the VK2735 clinical program, which has shown promising weight loss results compared to competitors. The recent agreement with CordenPharma to secure large-scale manufacturing capacity for VK2735's active pharmaceutical ingredient and its formulations indicates a proactive approach to meeting anticipated market demand and enhances Viking's operational capabilities. Furthermore, the ongoing pursuit of opportunities in new therapeutic areas such as Alzheimer's and hypertension, alongside the positive continuum of cardiovascular outcome trial data, bolsters confidence in long-term value creation driven by its product pipeline.

Bears say

Viking Therapeutics Inc's financial outlook is negatively impacted by increased research and development spending, which has led to a downward adjustment in the price target from $109 to $96. Key concerns include the potential for negative safety or efficacy findings in late-stage clinical trials that could further lower projections and generate uncertainty about market penetration and sales revenue for its candidates. Additionally, the company's fourth quarter earnings per share fell short of estimates, highlighting ongoing financial challenges and doubts regarding the successful advancement of its clinical programs.

Viking Therapeutics (VKTX) has been analyzed by 22 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 22 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $70.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $70.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.